News
Gain Therapeutics: Phase 1 Readout Awaits For Parkinson’s Drug With Great Potential (GANX)
Thesis I covered Gain Therapeutics, Inc. (NASDAQ:GANX) some months ago, having found both the company’s drug-discovery platform Magellan and drug…
Smartsheet Stock: Cheaper Than Ever, But I Wonder If It Is Smart? (NYSE:SMAR)
It hasn't been since 2019 when I last covered Smartsheet Inc. (NYSE:SMAR), which makes an update on the investment thesis…
Biden extends time frame to get credit toward student loan forgiveness
In an effort to fix administrative issues that resulted in student loan borrowers not qualifying for forgiveness, the Biden administration…
Ameriprise Stock: Good Business Strategy, But Little Upside Ahead
Ameriprise Financial (NYSE:AMP) has an interesting profile in the financial services sector, focusing its growth strategy in the advisory &…
Kforce: Sustained Demand For Technology-Based Solutions To Keep The Stock Elevated
Intro We wrote about Kforce Inc. (NYSE:KFRC) in February of this year when we were bullish on the technology segment…
New construction still popular as most Americans believe it’s a bad time to buy an existing home
New build homes are regaining popularity as existing home prices and interest rates remain high. A little over a million…
Genfit: Under The Radar Biotech With Upcoming Catalysts (NASDAQ:GNFT)
Genfit S.A. (NASDAQ:GNFT) is gearing up for two regulatory decisions in the coming months. The FDA and European Medicines Agency…
Harding Loevner International Small Companies Equity Composite Q1 2024 Report
What Happened US stocks outpaced international markets in the first quarter, due in no small part to ongoing interest in…